View in EDS HTML Full Text PDF Full Text

Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.

Saved in:
Bibliographic Details
Title: Impact of CCND1 amplification on the prognosis of hormone receptor-positive, HER2-negative breast cancer patients-correlation of clinical and pathological markers.
Authors: Hanf D; Department of Translational Medical Oncology, National Center for Tumor Diseases Dresden (NCT/UCC) and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Translational Medical Oncology, Faculty of Medicine, Carl Gustav Carus University Hospital, TUD Dresden University of Technology, Dresden, Germany.; Partner Site Dresden, German Cancer Consortium (DKTK), Heidelberg, Germany., Fasching P; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Comprehensive Cancer Center Alliance WERA (CCC), Erlangen, Germany.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany., Gass P; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Comprehensive Cancer Center Alliance WERA (CCC), Erlangen, Germany.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany., Matthias W Beckmann; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Comprehensive Cancer Center Alliance WERA (CCC), Erlangen, Germany.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany., Hack CC; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Comprehensive Cancer Center Alliance WERA (CCC), Erlangen, Germany.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany., Heindl F; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Comprehensive Cancer Center Alliance WERA (CCC), Erlangen, Germany.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany., Lothar Häberle; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., John N; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Erber R; Institute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Erlangen, Germany., Press MF; Department of Pathology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA., Rübner M; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany.; Comprehensive Cancer Center Alliance WERA (CCC), Erlangen, Germany.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany., Pöschke P; Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN) / Friedrich Alexander University of Erlangen-Nuremberg (FAU), Universitätsstrasse 21-23, 91054, Erlangen, Germany. patrik.poeschke@uk-erlangen.de.; Comprehensive Cancer Center Alliance WERA (CCC), Erlangen, Germany. patrik.poeschke@uk-erlangen.de.; Bavarian Center for Cancer Research (BZKF), Erlangen, Germany. patrik.poeschke@uk-erlangen.de.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2025 Feb; Vol. 210 (1), pp. 125-134. Date of Electronic Publication: 2024 Nov 26.
Publication Type: Journal Article
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1573-7217
DOI:10.1007/s10549-024-07545-x